Clinical Trial Update: Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 study of STX-241 in locally advanced or metastatic non-small cell lung cancer resistant to EGFR inhibitors. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• STX-241 (STX-241)

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: RECRUITING